Loading the company…
Loading the company…
In the last ten years FDA made 3 decisions for Endomagnetics (510(k) clearances, De Novo grants, PMA approvals and supplements) under the product codes MedaRep maps to 1 procedure family, the most in 2024 (1). The latest was on 2024-06-28.
| Family | Decisions on record |
|---|---|
| Breast biopsy & localization | 3 |
| Date | Kind | Number | Device |
|---|---|---|---|
| 2024-06-28 | 510(k) | K232865 | Magseed Pro Magnetic Marker System |
| 2023-01-21 | 510(k) | K222832 | Sentimag System |
| 2018-02-16 | 510(k) | K173587 | Magseed Magnetic Marker Systtem |
Decisions under the product codes mapped to the procedure families; devices filed under other codes are not here. Applicants are rolled up to Endomagnetics.
In 2025, Endomagnetics reported engagement with 85 surgeons and other clinicians in the states MedaRep covers, worth $54K in consulting, speaking, meals and travel for its device products, the most in California ($28K to 25). Royalties are left out.
Spend tied to a procedure counts the payments whose product names it. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing.Top states by spend: California ($28K, 25 engaged), New York ($9,734, 9 engaged), Idaho ($4,151, 3 engaged), Virginia ($3,332, 3 engaged), Kansas ($2,292, 2 engaged).